Quantification of serum hepatitis B surface antigen (HBsAg) helps the management of patients with chronic hepatitis B virus (HBV) infection. Median HBsAg levels differ significantly during the natural history of HBV infection, progressively declining from immune tolerance to inactive phase. The combination of an HBsAg <1000 IU/mL and HBV DNA <2000 IU/mL at a single time point accurately identifies true inactive carriers. During antiviral treatment, HBsAg levels decline more rapidly in patients under peg-interferon (Peg-IFN) than in those under nucleos(t)ide analogues (NUC), and in responders to peg-IFN compared to non responders suggesting that a response-guided therapy in both HBeAg-positive and -negative patients treated with Peg-IFN could improve to cost-effectiveness of this therapeutic approach. Given the low rates of HBsAg clearance on NUC therapy, new studies to test whether Peg-IFN and NUC combination fosters HBsAg decline in long-term responders to NUC, are being explored.
Clinical implications of HBsAg quantification in patients with chronic hepatitis B / M. Viganò, P. Lampertico. - In: SAUDI JOURNAL OF GASTROENTEROLOGY. - ISSN 1319-3767. - 18:2(2012 Mar), pp. 81-86.
|Titolo:||Clinical implications of HBsAg quantification in patients with chronic hepatitis B|
VIGANO', MAURO (Primo)
LAMPERTICO, PIETRO (Ultimo)
|Parole Chiave:||Chronic hepatitis B; HBsAg quantification; interferon|
|Settore Scientifico Disciplinare:||Settore MED/12 - Gastroenterologia|
|Data di pubblicazione:||mar-2012|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.4103/1319-3767.93805|
|Appare nelle tipologie:||01 - Articolo su periodico|